SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 224 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $427,638 | -6.9% | 15,511 | +1.6% | 0.00% | 0.0% |
| Q2 2023 | $459,106 | -19.1% | 15,273 | -2.5% | 0.00% | -20.0% |
| Q1 2023 | $567,470 | +5.4% | 15,663 | +3.8% | 0.01% | 0.0% |
| Q4 2022 | $538,439 | +9.7% | 15,095 | +4.0% | 0.01% | 0.0% |
| Q3 2022 | $491,000 | +17.7% | 14,515 | +0.7% | 0.01% | +25.0% |
| Q2 2022 | $417,000 | -10.3% | 14,412 | +0.3% | 0.00% | 0.0% |
| Q1 2022 | $465,000 | +11.5% | 14,376 | +0.5% | 0.00% | +33.3% |
| Q4 2021 | $417,000 | +8.3% | 14,304 | -1.0% | 0.00% | 0.0% |
| Q3 2021 | $385,000 | -12.7% | 14,442 | +0.8% | 0.00% | -25.0% |
| Q2 2021 | $441,000 | +9.7% | 14,321 | -6.6% | 0.00% | 0.0% |
| Q1 2021 | $402,000 | +4.7% | 15,337 | +0.5% | 0.00% | +33.3% |
| Q4 2020 | $384,000 | +16.4% | 15,254 | -3.8% | 0.00% | 0.0% |
| Q3 2020 | $330,000 | +17.4% | 15,853 | +33.9% | 0.00% | -25.0% |
| Q2 2020 | $281,000 | +26.6% | 11,841 | -3.9% | 0.00% | 0.0% |
| Q1 2020 | $222,000 | -73.3% | 12,316 | -64.8% | 0.00% | -60.0% |
| Q4 2019 | $830,000 | -51.0% | 34,984 | -43.2% | 0.01% | -52.4% |
| Q3 2019 | $1,693,000 | -37.0% | 61,600 | -24.2% | 0.02% | -32.3% |
| Q2 2019 | $2,689,000 | -4.9% | 81,259 | +0.7% | 0.03% | -8.8% |
| Q1 2019 | $2,828,000 | +5.8% | 80,711 | +0.3% | 0.03% | 0.0% |
| Q4 2018 | $2,673,000 | -29.9% | 80,475 | +6.2% | 0.03% | -5.6% |
| Q3 2018 | $3,814,000 | -15.5% | 75,743 | +0.5% | 0.04% | -20.0% |
| Q2 2018 | $4,511,000 | +21.2% | 75,369 | -7.3% | 0.04% | +18.4% |
| Q1 2018 | $3,722,000 | +8.4% | 81,261 | -5.7% | 0.04% | +15.2% |
| Q4 2017 | $3,434,000 | +226.4% | 86,161 | +227.6% | 0.03% | +153.8% |
| Q3 2017 | $1,052,000 | -6.8% | 26,301 | +0.4% | 0.01% | -18.8% |
| Q2 2017 | $1,129,000 | +38.2% | 26,201 | +0.4% | 0.02% | +45.5% |
| Q1 2017 | $817,000 | +26.9% | 26,101 | +2.4% | 0.01% | +22.2% |
| Q4 2016 | $644,000 | +1.7% | 25,501 | -0.4% | 0.01% | -10.0% |
| Q3 2016 | $633,000 | +72.5% | 25,601 | +42.2% | 0.01% | +100.0% |
| Q2 2016 | $367,000 | +36.9% | 18,001 | +2.3% | 0.01% | +66.7% |
| Q1 2016 | $268,000 | +20.2% | 17,601 | +6.0% | 0.00% | 0.0% |
| Q4 2015 | $223,000 | -2.6% | 16,601 | +1.8% | 0.00% | 0.0% |
| Q3 2015 | $229,000 | – | 16,301 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 426,500 | $11,754,340 | 3.96% |
| ASHFORD CAPITAL MANAGEMENT INC | 916,747 | $25,274,715 | 3.72% |
| ARMISTICE CAPITAL, LLC | 5,092,000 | $140,386,440 | 2.15% |
| S&T BANK/PA | 215,578 | $5,943 | 1.15% |
| Aristotle Capital Boston, LLC | 1,187,981 | $32,752,634 | 1.06% |
| RICE HALL JAMES & ASSOCIATES, LLC | 544,468 | $15,010,983 | 0.95% |
| Tributary Capital Management, LLC | 352,429 | $9,716,468 | 0.92% |
| Bridge City Capital, LLC | 65,297 | $1,800,238 | 0.91% |
| Integral Health Asset Management, LLC | 220,000 | $6,065,400 | 0.84% |
| Retirement Planning Co of New England, Inc. | 51,608 | $1,422,833 | 0.79% |